These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35460398)

  • 21. Drift, evolution, and divergence in biologics and biosimilars manufacturing.
    Ramanan S; Grampp G
    BioDrugs; 2014 Aug; 28(4):363-72. PubMed ID: 24567263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
    Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
    [No Abstract]   [Full Text] [Related]  

  • 24. [Biosimilars: opportunities and risks].
    Grieshaber-Bouyer R; Lorenz HM
    Internist (Berl); 2020 May; 61(5):522-529. PubMed ID: 32333085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
    Kim H; Alten R; Avedano L; Dignass A; Gomollón F; Greveson K; Halfvarson J; Irving PM; Jahnsen J; Lakatos PL; Lee J; Makri S; Parker B; Peyrin-Biroulet L; Schreiber S; Simoens S; Westhovens R; Danese S; Jeong JH
    Drugs; 2020 Feb; 80(2):99-113. PubMed ID: 32002851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biosimilars, no generic biologicals!].
    Knuts B
    J Pharm Belg; 2016 Dec; (4):24-29. PubMed ID: 30281245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory evaluation of biosimilars throughout their product life-cycle.
    Kang HN; Knezevic I
    Bull World Health Organ; 2018 Apr; 96(4):281-285. PubMed ID: 29695884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PANLAR consensus statement on biosimilars.
    Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
    Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Biologics and Biosimilars in Rheumatology.
    Sharma SK
    J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.
    Kabir ER; Moreino SS; Sharif Siam MK
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologicals and biosimilars: safety issues in Europe.
    Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
    Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar biologics in India: A story of access or potential for compromise?
    Jois R; Mukherjee S; Rajeswari S; Rath PD; Goyal V; Gupta D
    Indian J Med Res; 2020 Nov; 152(5):456-467. PubMed ID: 33707387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The regulatory landscape of biosimilars: Algeria's efforts and progress made from 2006 to 2021.
    Benahzil MA; Hadjaz IM; Mansouri K
    Ann Pharm Fr; 2022 Jul; 80(4):440-447. PubMed ID: 34767827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
    Cohen AD; Wu JJ; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; de la Cruz C; Skov L; Zachariae C; Young HS; Foley P; van der Walt JM; Naldi L; Prens EP; Blauvelt A
    Br J Dermatol; 2017 Dec; 177(6):1495-1502. PubMed ID: 28646580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.
    Carl DL; Laube Y; Serra-Burriel M; Naci H; Ludwig WD; Vokinger KN
    JAMA Netw Open; 2022 Dec; 5(12):e2244670. PubMed ID: 36459139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
    Chen BK; Yang YT; Bennett CL
    Drugs; 2018 Nov; 78(17):1777-1781. PubMed ID: 30446980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues.
    Blandizzi C; Meroni PL; Lapadula G
    Clin Ther; 2017 May; 39(5):1026-1039. PubMed ID: 28416374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.